E-LIB Suche - Ergebnisse für: Ozelo, MC

1

EE51 Analysis of Direct Costs of Treating Severe Hemophilia..:

Ozelo, MC ; Yamaguti-Hayakawa, G.G. ; Ramos, TRM..
Value in Health. 27 (2024) 6 - p. S66 , 2024

Link: https://doi.org/10.1016/..

2

BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRA..:

Ozelo, MC ; Mahlangu, J ; Madan, B...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S451-S452 , 2023

Link: https://doi.org/10.1016/..

3

AS DIFICULDADES LABORATORIAIS PARA O DIAGNÓSTICO CONFIRMATÓ..:

Moura, MS ; Assis, RA ; Anjos, ACMD...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S488-S489 , 2023

Link: https://doi.org/10.1016/..

4

O IMPACTO DA TERAPIA GÊNICA NA SAÚDE MUSCULOESQUELÉTICA DE ..:

Yamaguti-Hayakawa, GG ; Ricciardi, JBS ; Frade-Guanaes, JO...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S468 , 2023

Link: https://doi.org/10.1016/..

5

HEPATITE C EM PACIENTES COM DOENÇA HEMORRÁGICA HEREDITÁRIA:..:

Foschi, NM ; Siqueira, LH ; Rocha, DMC...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S707 , 2023

Link: https://doi.org/10.1016/..

6

PERFIL DE CITOCINAS PRODUZIDAS EM PACIENTES COM HEMOFILIA A..:

Frade-Guanaes, JO ; Racanelli, AP ; Siqueira, LH...
Hematology, Transfusion and Cell Therapy. 44 (2022) - p. S293-S294 , 2022

Link: https://doi.org/10.1016/..

7

EXPRESSÃO DE BAFF (B-CELL ACTIVATING FACTOR) E RESPOSTA IMU..:

Frade-Guanaes, JO ; Racanelli, AP ; Siqueira, LH...
Hematology, Transfusion and Cell Therapy. 43 (2021) - p. S224-S225 , 2021

Link: https://doi.org/10.1016/..

8

RESULTS FROM A 52-WEEK, NONINTERVENTIONAL STUDY OF BRAZILIA..:

Yamaguti-Hayakawa, GG ; Villaça, PR ; Lorenzato, C...
Hematology, Transfusion and Cell Therapy. 43 (2021) - p. S232-S233 , 2021

Link: https://doi.org/10.1016/..

9

von Willebrand disease: proposing definitions for future re..:

Connell, NT ; James, PD ; Brignardello-Petersen, R...
https://discovery.ucl.ac.uk/id/eprint/10120590/7/Abdul-Kadir_definition%20paper.pdf. , 2021

Link: https://discovery.ucl.ac..

10

ASH ISTH NHF WFH 2021 guidelines on the management of von W..:

Connell, NT ; Flood, VH ; Brignardello-Petersen, R...
Connell , NT , Flood , VH , Brignardello-Petersen , R , Abdul-Kadir , R , Arapshian , A , Couper , S , Grow , JM , Kouides , P , Laffan , M , Lavin , M , Leebeek , F , O'Brien , SH , Ozelo , MC , Tosetto , A , Weyand , AC , James , PD , Kalot , MA , Husainat , N & Mustafa , RA 2021 , ' ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease ' , Blood advances , vol. 5 , no. 1 , pp. 301-325 . https://doi.org/10.1182/bloodadvances.2020003264. , 2021

Link: https://pure.eur.nl/en/p..

11

ASH ISTH NHF WFH 2021 guidelines on the management of von W..:

Connell, NT ; Flood, VH ; Brignardello-Petersen, R...
https://discovery.ucl.ac.uk/id/eprint/10119839/1/VWD%20Tx%20guideline.pdf. , 2021

Link: https://discovery.ucl.ac..

12

Extending recombinant factor IX Fc fusion protein dosing in..:

Shapiro, AD ; Pasi, KJ ; Ozelo, MC...
Res Pract Thromb Haemost. , 2018

Link: https://qmro.qmul.ac.uk/..

13

BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRA..:

MC Ozelo ; J Mahlangu ; B Madan...
http://www.sciencedirect.com/science/article/pii/S2531137923010180. , 2023

Link: https://doi.org/10.1016/..

14

O IMPACTO DA TERAPIA GÊNICA NA SAÚDE MUSCULOESQUELÉTICA DE ..:

GG Yamaguti-Hayakawa ; JBS Ricciardi ; JO Frade-Guanaes...
http://www.sciencedirect.com/science/article/pii/S2531137923010465. , 2023

Link: https://doi.org/10.1016/..

15

AS DIFICULDADES LABORATORIAIS PARA O DIAGNÓSTICO CONFIRMATÓ..:

MS Moura ; RA Assis ; ACMD Anjos...
http://www.sciencedirect.com/science/article/pii/S2531137923010805. , 2023

Link: https://doi.org/10.1016/..